Melanoma

799

Pipeline Programs↗

213

Active Trials↗

180

Companies Involved↗

Melanoma is a highly competitive landscape with 799 programs across 180 companies. The most active players are PrimeVax Immuno-Oncology Inc., Daiichi Sankyo, Risen (Suzhou) Pharma Tech Co., Ltd.. 30 therapies are approved with 97 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

100/100

Pipeline Velocity

65/100

Mech. Concentration

4/100

Completion Rate

71/100

Attrition Rate

20/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

PrimeVax Immuno-Oncology Inc.

3 programs

Daiichi Sankyo

2 programs

Risen (Suzhou) Pharma Tech Co., Ltd.

2 programs

Graceway Pharmaceuticals, LLC

2 programs

Day One Biopharmaceuticals

1 program

TILT Biotherapeutics Ltd.

1 program

Analysis

Modality Breakdown

75%

Small molecule

542 of 727 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 727 classified programs, each share of the total. Modality classified for 99% of 948 pipeline programs.

Analysis

Trial Status

1,129

clinical trials

Completed567 · 50%

Terminated181 · 16%

Unknown status111 · 10%

Recruiting100 · 9%

Active, not recruiting87 · 8%

Withdrawn41 · 4%

Other42 · 4%

Clinical Trials

Trial Activity

1129 trials

Camrelizumab Plus Apatinib and Temozolomide as Neoadjuvant in High Risk Acral Melanoma

Recruiting·PPeking University Cancer Hospital & Institute·Phase 2·NCT05512481·60 enrolled

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Recruiting·SWOG Cancer Research Network·Phase 2·NCT04511013·112 enrolled

A Phase II Clinical Trial on Neo-adjuvant Pembrolizumab in Patients With pT3b-T4a/b cN0M0 Melanoma.

Recruiting·UUniversitair Ziekenhuis Brussel·Phase 2·NCT07448831·49 enrolled

Neo-adjuvant Immunotherapy in Patients With Localized Melanoma

Recruiting·UUNICANCER·Phase 2·NCT07230613·50 enrolled

Evolution of Metabolic and Immune Dysfunction in In-transit Melanoma

Recruiting·—·N/A·NCT04658303·20 enrolled

SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma

Recruiting·—·Phase 3·NCT06794775·128 enrolled

Evaluation of Hypoxia in Primary Melanoma

Recruiting·—·N/A·NCT06831071·50 enrolled

RWS of Tunlametinib in NRAS-Mutant Advanced Melanoma

Recruiting·FFudan University·Phase 4·NCT07445022·110 enrolled

A Study of GC101 TIL in Advanced Melanoma

Recruiting·SShanghai Juncell Therapeutics·Phase 2·NCT06703398·98 enrolled

OH2 Injection in Melanoma

Recruiting·BBinhui Biopharmaceutical Co., Ltd.·Phase 3·NCT05868707·340 enrolled

A Phase II Trial of LM103 in Advanced Melanoma

Recruiting·SSuzhou BlueHorse Therapeutics Co., Ltd.·Phase 2·NCT07310784·92 enrolled

Cryoablation+Ipilimumab+Nivolumab in Melanoma

Recruiting·MMassachusetts General Hospital·Phase 2·NCT05779423·37 enrolled

Neoadjuvant SHR-1210 Plus Apatinib for Resectable Stage III-IV Acral Melanoma

Recruiting·—·Phase 2·NCT04331093·40 enrolled

A Study of Lifileucel (Tumor-infiltrating Lymphocytes) in Adults With Advanced Melanoma

Recruiting·IIovance Biotherapeutics, Inc.·Phase 2·NCT07288203·100 enrolled

A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma

Recruiting·AAura Biosciences·Phase 3·NCT06007690·100 enrolled

Page 1 of 76

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)